Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Perflutren (compound)

Name: perflutren
PubChem Compound ID: 6432
Molecular formula: C3F8
Molecular weight: 188.019 g/mol
MRX-115; FC 218; FS069; Freon 218; Definity; Definity (TN); HFC 218; UN 2424; OCTAFLUOROPROPANE; FC 218 (refrigerant).
show more »
Name: perflutren
Name (isomeric): DB00556
Drug Type: small molecule
Brand: Perfluoropropane, Freon 218, Genetron 218, Perflutren [USAN], Propane, octafluoro-, Perfluoropropaneminimum, Definity, Perfluoropropane 99+%, Octafluoropropane
Category: Ultrasound contrast agent, Contrast Media
CAS number: 76-19-7
Indication: Use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. It provide contrast enhancement of the endocardial borders during echocardiography. The perflutren lipid microspheres exhibit lower acous...
show more »
Mechanism of Action:
Perflutren is comprised of gas-filled microspheres that are injected or infused into the body. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the ...
show more »
Biotransformation: OFP is not metabolized. The phospholipid components of the microspheres are thought to be metabolized to free fatty acids.
Half Life: The mean half-life of OFP in blood 1.9 minutes
Affected organisms: Humans and other mammals
Drug interaction:
TacrolimusAdditive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
LumefantrineAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
ThiothixeneMay cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
VorinostatAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
ToremifeneAdditive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
show more »